Российский кардиологический журнал | |
WAYS OF MENOPAUSAL HORMONAL THERAPY IN CORRECTION OF METABOLIC DISORDERS AND ANGIOPROTECTION IN POSTMENOPAUSAL WOMEN | |
I. N. Barykina1  V. O. Smirnova1  S. V. Nedogoda1  V. Yu. Khripaeva1  R. V. Palashkin1  A. S. Salasyuk1  | |
[1] Volgograd State Medical University; | |
关键词: drospirenon; metabolic syndrome; menopausal hormonal therapy; postmenopause; vascular elasticity; vascular age; | |
DOI : 10.15829/1560-4071-2016-4-70-75 | |
来源: DOAJ |
【 摘 要 】
Aim. To compare effectiveness of non-drug therapy together with menopausal hormonal therapy (MHT) — estradiol hemihydrate 1 mg/drospirenon 2 mg (Angeliq® Bayer Pharma AG (Germany)) related to normalization of anthropometric and metabolic parameters, elasticity values and vascular age in women with metabolic syndrome (MS) in postmenopause.Material and methods. The open-label prospective comparative controlled randomized study in 2 parallel groups. Sixty female patients (mean age 55,26±5,63 y.) with MS (according to IDF 2005 criteria) were randomized equally 1:1 into 2 groups. During 36 weeks patients of 1st group (n=30) received life style modification recommendations and monotherapy by Angeliq® , patients from 2nd group (controls, n=30) only followed life style modification. Groups were comparable by baseline clinical and demographic parameters. All patients received instructions for diet, physical activity and life style changes. Anthropometric, metabolic and instrumental assessments were done at baseline, in 12 and 36 weeks of therapy.Results. Prescription of MHT in MS patients in postmenopause led to body weight decrease, decrease of percent composition of visceral fat, improvement of metabolic parameters, vascular elasticity and decrease of vascular age. There were no adverse events related to the drug during the study.Conclusion. Angeliq® is effective and safe medication for low-dosage continuous combination MHT in menopausal MS that facilitates improvement of anthropometric parameters, vascular elasticity and vascular ageing.
【 授权许可】
Unknown